stockrow
Friday 6 November 2026
Export CELC’s income statement to Excel — free account
Celcuity, Inc.
CELC Healthcare Biotechnology
- EPS
- −38.5%
- Free cash flow
- −53.3%
- Total debt
- +658.7%
Quarter to June 2026, against a year earlier
66.82
2.78
+4.34%
Follow CELC
Alert me
Celcuity, Inc. (CELC) Net income
Celcuity, Inc.'s net income for fiscal 2025 was −$177.0M, compared with −$111.8M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$226.5M. Over the past ten years it has ranged from −$177.0M (fiscal 2025) to −$2.3M (fiscal 2015) — the current reading is the lowest in ten years. Net income has fallen for 6 consecutive fiscal years. Celcuity, Inc. ranks 536th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$177.0M | — |
| FY2024 | −$111.8M | — |
| FY2023 | −$63.8M | — |
| FY2022 | −$40.4M | — |
| FY2021 | −$29.6M | — |
| FY2020 | −$9.5M | — |
| FY2019 | −$7.4M | — |
| FY2018 | −$7.5M | — |
| FY2017 | −$6.3M | — |
| FY2016 | −$3.3M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | −$78.9M | — |
| Mar 2026 | −$52.8M | — |
| Dec 2025 | −$51.0M | — |
| Sep 2025 | −$43.8M | — |
| 38 more quarters | Free account |
Against its own ten years
Low −$177.0M
High −$2.3M
Ten-year median
−$9.5M
Current reading's percentile
9
Net income against peers
| Company | Net income |
|---|---|
| TLX Telix Pharmaceuticals Limited compare | $31.7M |
| ELVN Enliven Therapeutics, Inc. compare | −$105.9M |
| CELC Celcuity, Inc. | −$226.5M |
| DNLI Denali Therapeutics Inc. compare | −$314.4M |
| IDYA IDEAYA Biosciences, Inc. compare | −$420.0M |
| VRDN Viridian Therapeutics, Inc. compare | −$453.6M |
| DYN Dyne Therapeutics, Inc. compare | −$519.4M |
| VKTX Viking Therapeutics, Inc. compare | −$627.2M |
| TARS Tarsus Pharmaceuticals, Inc. compare | −$702.2M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item